KATARINA LECLAIR: Open Payments
NPI 1811462450 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,176 in 36 payments from 17 companies in 2025. Trend: 2023 $598 · 2024 $1,300 · 2025 $1,176
Food & beverage: $1,176
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $219 |
| SCPHARMACEUTICALS INC. | 3 | $146 |
| Lilly USA, LLC | 4 | $145 |
| Calliditas Therapeutics US Inc. | 4 | $121 |
| Travere Therapeutics, Inc. | 1 | $109 |
| AKEBIA THERAPEUTICS INC | 2 | $81 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $51 |
| Novo Nordisk Inc | 2 | $50 |
| Fresenius USA Marketing, Inc. | 2 | $44 |
Products named: FUROSCIX, Vanrafia, TARPEYO, Fabhalta, Vafseo, JARDIANCE, Kerendia, VELPHORO.
Industry payments across MI — which companies pay providers there.
